Asian Activities Report for September 5, 2011: Trafford Resources (ASX:TRF) Commenced Exploration at Prospective Peterlumbo Tenement
Sydney, Sep 5, 2011 AEST (ABN Newswire) - Trafford Resources Limited (ASX:TRF) has commenced an exploration programme on its 100% owned Peterlumbo tenement in South Australia. The Peterlumbo tenement is adjacent to and directly along strike from the recently discovered high grade silver mineralisation reported by Investigator Resources Limited (ASX:IVR). A review of historical data within the Peterlumbo tenement has indicated a multi-commodity soil geochemistry anomaly (gold, silver, uranium, thorium, lead). Results from the exploration programme are expected shortly and will assist in defining an ongoing exploration programme.
Energy Ventures Limited (ASX:EVE) has commenced a diamond drilling programme at its Maybell uranium project in USA. Based on historical uranium production records and reported exploration results, there is significant potential at the Maybell project area for near surface uranium resources. Subject to the results of the current drilling programme, further drill testing will be taken on the exploration targets.
Rex Minerals Limited (ASX:RXM) has received further drilling results from its 100% owned Hillside Copper Project in South Australia. Drilling has discovered new extensions to the current copper-gold mineralisation and returned additional high grade results, which will help to optimise the mine plan during the pre-feasibility study.
Minotaur Exploration Limited (ASX:MEP) has discovered a large copper-gold mineralized system at the Cormorant Prospect in western Queensland. Recent drilling has revealed significant widths and a greatly expanded strike extent, confirming Cormorant as an extensive iron oxide copper-gold prospect over a strike in excess of 10 kilometres. Further geophysical surveys and drilling are being planned to identify more copper-rich portions of this new mineralized discovery.
Indian-based pharmaceutical giant Lupin Limited (BOM:500257) has received final approval from the US Food and Drug Administration for the new drug application for Tramadol Hydrochloride Extended Release Tablets ("Tramodol HCI ER"), 100, 200, 300 mg strengths. Lupin will begin shipping the drug to US shortly. Tramodol HCI ER is a centrally acting synthetic analgesic for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.